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Abstract Patients with lymphoproliferative disorders,
candidate to autologous stem cell transplantation (ASCT),
require mobilization with chemotherapy and granulocyte
colony -stimulating factor (G-CSF). This study looked for
differences in hematopoietic peripheral stem cells (HPSCs)
mobilization in response to the three available G-CSFs,
namely lenograstim, filgrastim, and pegfilgrastim. Between
2000 and 2012, 146 patients (66 M and 80 F) who
underwent ASCT for multiple myeloma, non-Hodgkin’s
lymphoma or Hodgkin’s lymphoma were studied. All
patients received induction therapy and then a mobilization
regimen with cyclophosphamide plus lenograstim, or fil-
grastim, or pegfilgrastim. From days 12 to 14, HPSCs were
collected by two to three daily leukaphereses. Our results
show that high-dose cyclophosphamide plus lenograstim
achieved adequate mobilization and the collection target
more quickly and with fewer leukaphereses as compared to
filgrastim and pegfilgrastim. No differences between the
three regimens were observed regarding toxicity and days
to WBC and platelet recovery. Thus, lenograstim may
represent the ideal G-CSF for PBSC mobilization in
patients with lymphoproliferative diseases. Further studies
are needed to confirm these results and better understand
the biological bases of these differences.
Keywords Cell mobilization  Granulocyte
colony-stimulating factor  Pegylated G-CSF  Peripheral
blood progenitor cells  Recombinant human glycosylated
G-CSF  Recombinant non-glycosylated G-CSF
Introduction
In the current clinical practice, dose-intensive chemothera-
py followed by peripheral blood stem cell transplantation
(PBSCT) is frequently employed in the treatment of a
variety of hematological malignancies. Granulocyte col-
ony-stimulating factor (G-CSF), the primary regulator of
granulopoiesis used to mobilize stem cells from bone
marrow to peripheral blood in lymphoproliferative disor-
ders, is primarily used for the prevention of neutropenia
and reduction in its complications after chemotherapy or
myelosuppressive therapy [1].
Granulocyte colony-stimulating factor (G-CSF), that has
to a large extent replaced the use of granulocyte macro-
phage (GM)-CSF, induces the proliferation and differenti-
ation of myeloid precursor cells, chemotaxis, respiratory
burst and antigen expression of neutrophils [2, 3]. We have
observed important differences using the three available
G-CSFs in HPSCs mobilizing regimens.
As previously described [4], lenograstim (glycosylated
rHu G-CSF) is obtained from Chinese hamster ovarian
cells, which consists of 174 amino acids with 4 % glyco-
sylation. Filgrastim (non-glycosylated Hu G-CSF) is pro-
duced using Escherichia coli, with a methionine group at
its N-terminal end [3]. The pegylated form of non-gly-
cosylated Hu G-CSF (pegfilgrastim) is obtained by the
attachment of the polyethylene glycol (PEG) moiety, which
reduces renal excretion and masks the proteolytic cleavage
sites, resulting in elevated G-CSF serum levels for up to
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14 days after a single injection [5]. Actually, only leno-
grastim is fully authorized in USA and EU for mobiliza-
tion, while the other G-CSFs lack in this indication.
In some patients, the number of mobilized CD34? cells
is not sufficient to perform a successful stem cell trans-
plantation due to bone marrow damage by neoplastic pro-
liferation and/or chemoradiotherapy. To improve the
collection of CD34? cells, the mobilization procedure can
be repeated or an alternative chemotherapy regimen can be
chosen. Recently, in patients with non-Hodgkin lymphoma
(NHL) or multiple myeloma (MM) with a poor yield of
CD34? cells, the new drug plerixafor (Mozobil) can be
administered before apheresis to increase the number of
circulating CD34? cells. Plerixafor is a derivative of bi-
cyclam, reversible and selective antagonist of the CXCR4
chemokine receptor that acts by blocking the binding
between this receptor expressed on hematopoietic stem
cells and its ligand, namely the stromal cell-derived factor-
1a (SDF-1a), also called CXCL12, expressed on stromal
cells. Its use increases the level of functional HPCs in the
peripheral blood, with long-term resettlement [6–10].
Since no data on the comparison between the three
G-CSFs are available, in this study we have compared them
to indentify the best mobilizer.
Patients and methods
Patients
A total of 146 patients (66 M and 80 F, Table 1) who
underwent ASCT for MM (89 pts), NHL (46 pts) or
Hodgkin lymphoma (HL, 11 pts) between 2000 and 2012
were consecutively included in this controlled, non-ran-
domized study. Inclusion criteria were those for ASCT,
namely age\70 years, serum creatinine level\200 mmol/
L, cardiac ejection fraction [50 %, DLCO (diffusing
capacity of the lung for carbon monoxide) [50 %, no
active infection or other disease causing co-morbidity
[11, 12].
The study, which was carried out according to the
Helsinki Declaration, was approved by the local ethical
committee. All patients gave their informed consent.
Treatment plan
All patients received induction therapy with 4 cycles of
vincristine/adriamycin/dexamethasone (VAD—54 MM
pts), 4 cycles of bortezomib/thalidomide/dexamethasone
(VTD—35 MM pts), or 3 cycles of ifosfamide/epirubicin/
vincristine (IEV) (LNH and LH pts), and then a mobili-
zation regimen with cyclophosphamide 3–7 g/mq at day 0
plus glycosylated Hu G-CSF at the dose of 10 lg/kg/daily
(Arm A) from day 5, or non-glycosylated rHu G-CSF (Arm
B) from day 5 or pegfilgrastim (Arm C) at the dose of 6 mg
at day 6. From day 12 to day 14, PBSCs were collected in
two to three daily leukaphereses, and their content in
CD34? cells was evaluated by FACS analysis. If the
minimum HPC target (C4 9 106/CD34? cells/Kg bw) was
not reached, after at least 1 month, Plerixafor was admin-
istered and the mobilizing procedure was repeated. This
last procedure was not included in the study.
Efficacy and toxicity
The number of CD34? cells collected and the number of
leukaphereses needed to reach their collection target were
evaluated. Moreover, the number of days required to
recover normal WBC and platelet counts, assessment of
toxicity and the percentage of patients who achieved the
collection target in a single course of mobilization (high-
dose cyclophosphamide plus G-CSF, followed by three
leukaphereses) were estimated.









Numbers 146 81 31 34
Sex: M/F 66/80 29/52 19/12 18/16
Age, median (range) years 53.7 (36–64) 52.2 (36–64) 49.5 (34–60) 48.3 (38–63)
MM/NHL/HL 89/46/11 63/13/5 12/15/4 14/18/2
Status at mobilization: CR/PR/SD/PD 22/86/28/10 13/47/17/4 4/19/5/3 5/20/6/3
Patients receiving radiotherapy 12 6 2 4
Patients with bone marrow involvement 17 7 4 6
Mobilizing chemotherapy (MM/NHL/HL)
CTX 7 g/m2 0/46/11 0/13/6 0/15/3 0/18/2
CTX 4 g/m2 74/0/0 53/0/0 10/0/0 11/0/0
CTX 3 g/m2 15/0/0 9/0/0 3/0/0 3/0/0
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Statistical analysis
Data were analyzed with the SPSS, Chicago, IL, software
package. All results are presented as median ±1 SD. The
medians were compared with the Mann–Whitney U Test;
p values\0.05 were considered significant.
Results
A total of 81 patients (29 M and 52 F, median age
52.2 years, range 36–64) were enrolled in Arm A; 31
patients (19 M and 12 F, median age 49.5 years, range
34–60) in Arm B and 34 patients (18 M and 16 F, median
age 48.3 years, range 38–63) in Arm C. At the time of
mobilization, 22 patients had achieved complete remission,
86 partial remission, 28 stable disease and 10 disease
progression.
Mobilization and leukapheresis
A significantly higher CD34? collection was obtained
from the patients in Arm A (11.6 ± 1.1 9 106 CD34?/Kg
bw) versus Arm B (10.04 ± 0.4 9 106 CD34?/Kg bw)
(p\ 0.01) versus Arm C (10.76 ± 0.4 9 106 CD34?/Kg
bw) (p\ 0.05) (Fig. 1a). The percentage of patients who
reached the minimum collection target after two leuka-
phereses was higher in those treated with lenograstim
(78 %) compared with those who were given filgrastim
(48 %, p\ 0.001) and pegfilgrastim (56 %, p\ 0.005).
Thus, glycosylated G-CSF provided more effective mobi-
lization of bone marrow HPSCs.
No differences were observed among patients with MM,
NHL or HL, nor according to the doses of cyclophospha-
mide (3, 4 or 7 g/m2) employed. More precisely, the fol-
lowing mobilization yields were achieved. Arm A patients:
(a) with MM: 14.21 ± 2.8 9 106 CD34?/kg bw; (b) with
NHL: 16.14 ± 3.6 9 106 CD34?/kg bw; and (c) with HL:
15.81 ± 3.8 9 106 CD34?/kg bw (p: n.s.). Arm B:
patients: (a) with MM: 10.82 ± 2.33 9 106 CD34?/kg
bw; (b) with NHL: 12.23 ± 1.9 9 106 CD34?/kg bw; and
(c) with HL: 12.84 ± 2.84 9 106 CD34?/kg bw (p: n.s.);
Arm C patients: (a) with MM: 11.82 ± 2.24 9 106
CD34?/kg bw; (b) with NHL: 11.92 ± 3.3 9 106 CD34?/
kg bw; and (c) with HL: 13.36 ± 2.59 9 106 CD34?/kg
bw (p: n.s.).
The percentage of patients who reached the minimum
collection target after two leukaphereses were 79 % in MM
patients; 81 % in NHL patients and 78 % in patients with
HL in Arm A (p: n.s.); 46, 48 e 48 % in Arm B (p: n.s.); 59,
61 e 54 % in Arm C (p: n.s.).
Finally, no significant differences were observed among
patients with different lymphoma subtypes or with bone
marrow involvement.
Adverse events
Toxicity associated with the three regimens was similar in
terms of bone pain, fatigue, fever, mucositis and infe-
ctions (Table 2). All infections were treated with anti-
biotics and resolved following the recovery of a normal
leucocyte count. Finally, no differences were observed
within each group of patients in terms of days to WBC
recovery C500 and C1,000/mm3 (Fig. 1b) and platelets to
C50,000/mm3 (Fig. 1c). No platelet transfusions were
needed.
Fig. 1 Collection of CD34? cells (a) and differences observed in
terms of days to WBC recovery C500 and C1,000/mm3 (b) and
platelets C50,000/mm3 (c) in patients treated with lenograstim,
filgrastim and pegfilgrastim
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Discussion
High-dose chemotherapy followed by ASCT is considered
the standard of care for young patients with newly diag-
nosed MM, in high-risk NHL and HL, in whom in several
randomized studies [8, 12–14], this treatment has been
shown to induce an increased rate of complete response,
prolonged overall survival and reduced side effects com-
pared with conventional chemotherapy.
Mobilization of HPSCs in cancer patients is a routine
practice in high-dose therapy, followed by ASCT [8–10].
The mobilizing regimen usually consists of cyclophos-
phamide (3–7 g/mq) or disease-specific agents, in combi-
nation with an hematopoietic cytokine, usually G-CSF,
which mobilizes HPSCs into the bloodstream, in particular
when administered after myelosuppressive chemotherapy
[12].
We analyzed differences in HPSCs mobilization in
response to lenograstim, filgrastim or pegfilgrastim in
patients with MM and lymphomas with the aim of determi-
ning which of the three G-CSFs was more effective in
HPSCs mobilization.
In a previous study, we have already investigated the
role of G-CSF glycosylation [15]. It modifies the chemical
properties of G-CSF, including a higher molecular stiff-
ness, pH, temperature and elastase resistance that result in a
higher plasma half-life. Furthermore, glycosylation reduces
the formation of aggregates and increases receptor affinity,
causing an increase in bioavailability and molecular
activity. Glycosylation of G-CSF is also associated with
additional biological effects. For example, neutrophils
exposed in vitro to non-glycosylated G-CSF exhibit
reduced motility, morphological abnormalities, increased
spontaneous actin polymerization and RhoA activation, a
more immature phenotype and a slight reduction in the
release of reactive oxygen species (ROS) compared with
those exposed to glycosylated G-CSF. These features
contribute to the impairment of all biological functions of
these cells in response to external stimuli. Consistent with
these findings, neutrophils exposed to non-glycosylated
G-CSF may be less effective in preventing febrile episodes
in patients with chemotherapy-related neutropenia when
compared with those exposed to glycosylated G-CSF [16,
17].
Previous studies have shown that a lower dose of gly-
cosylated G-CSF is as effective as the standard dose of
non-glycosylated G-CSF for PBPC mobilization in patients
undergoing ASCT. Furthermore, a more rapid mobilization
has been observed in patients receiving lenograstim
(median time to collection: 12 days) than in those receiving
filgrastim (median time to collection: 13 days), which is in
line with our results [18, 19].
The randomized trial conducted by the Italian group has
shown a lower incidence of febrile episodes during the
period of neutropenia in MM patients receiving lenogra-
stim versus those administered filgrastim after high-dose
cyclophosphamide for stem cell mobilization [1]. Patients
treated with cyclophosphamide were randomly assigned to
receive filgrastim or lenograstim. The lenograstim group
presented not just a significantly higher absolute CD34?
cell number compared with the filgrastim group but also a
less number of days (8 days against 9 of the arm B) needed
to reach the target threshold of CD34? cells, while no
differences were detected in terms of collection efficacy.
Pegfilgrastim results from the addition of a monomethoxy
PEG to filgrastim, decreasing its serum clearance and
markedly increasing its half-life. In fact, the G-CSF can be
detected in the serum up to 14 days after a single admi-
nistration of subcutaneous pegfilgrastim. Furthermore, in
this way, its metabolism shifts totally to mature neutro-
phils. The growth factor would remain unchanged and
active until the reconstitution of the number of circulating
granulocytes.
Although pegfilgrastim is licensed for the prophylaxis of
febrile neutropenia after cytotoxic chemotherapy, it is also
an effective mobilizer of CD34? cells, although not yet
officially approved. In fact, pegfilgrastim compared
favorably with the other G-CSFs after mobilizing chemo-
therapy for autologous HSC collection. The administration
of pegfilgrastim following high-dose therapy and ASCT
shortened the time to myeloid recovery when compared
with conventional G-CSF. Plasma G-CSF levels were
about 1 log higher with pegfilgrastim, but in the setting of
autologous ASCT, this did not result into a faster hema-
topoietic recovery. Only few data are available on the
biological effects of pegfilgrastim, which suggest that












Fever 12 6 3 3
Fatigue 5 2 1 2
Bone pain 7 3 2 2
Pseudomonas
infection
2 0 1 1
Mucositis grade
II
4 2 1 1
Staphylococcal
infection




4 1 0 3
Nausea 9 2 4 3
Cough 2 2 0 0
148 Clin Exp Med (2015) 15:145–150
123
pegfilgrastim stimulation results in different functional
properties of hematopoietic stem and progenitor cells
compared with conventional G-CSF [20, 21].
Bassi et al. [22] compared the use of this type of growth
factor with standard G-CSF in 64 patients with NHL using
high-dose chemotherapy. At mobilization chemotherapy,
the first 26 patients used unconjugated G-CSF, while the
remaining 38 patients received pegfilgrastim. At the time
of harvest, 25 patients collected stem cells after the use of
G-CSF and 36 in the peg group. No statistically significant
differences were observed in median peripheral CD34?
cells mobilized (77 vs. 71 lL) and in collected CD34?
cells (12.3 9 106/kg vs. 9.4 9 106/kg; p = 0.76). In the
peg group, all patients collected the target CD34? cells
with a single apheresis with a greater proportion of
‘‘optimal’’ mobilizers (83 vs. 64 %; p = 0.05) showing
that a single dose of pegfilgrastim could be a valid alter-
native to unconjugated G-CSF to mobilize CD34? cells in
lymphoma patients.
Our study shows that the glycosylated form of G-CSF
provides the best results in the mobilization compared to
non-glycosylated form and to pegylated form. This was
evident both in terms of collection of target HPSCs and the
number of leukaphereses required to achieve it, lower than
the other two regimens. The patients included in the
present study were well balanced between Arm A (gly-
cosylated Hu G-CSF), Arm B (non-glycosylated rHu
G-CSF) and Arm C (pegylated form), and there were no
differences between groups that could affect the yield of
HPSCs. There were no significant differences among the
different diseases in terms of minimum number of CD34?
cells collected and the number of apheresis necessary to
achieve the target, (4–6 9 106 CD34?/Kg b.w.) and even
among patients treated with 3, 4 or 7 g/m2 of cyclophos-
phamide. An average of two aphereses was sufficient both
in patients with and without bone marrow involvement.
Finally, radiotherapy did not affect the apheretic yield.
These findings indicate that, despite the three G-CSF are
all safe in the mobilization procedure, lenograstim may
represent the ideal partner of cyclophosphamide for
mobilization of PBSCs in patients with lymphoprolifera-
tive disorders candidate to autologous transplantation.
Our report suffers from some limitations. The number of
HL patients was not sufficient to determine any difference
between the two G-CSF types in the disease. Also,
patients’ accrual by a single institution cannot allow a
phase III randomized study. However, center-to-center
variations in the ASCT procedures prevented us to plan a
multicenter phase III trial. Our study included three types
of hematologic malignancies in order to reach a sufficiently
large population to be examined. We did not monitor
serum G-CSF levels or other parameters related to the
mobilization process, which might have possibly revealed
some clues for the lack of between-group differences. This
kind of parameters, however, may be studied in a pro-
spective randomized fashion.
Larger randomized trials are needed to confirm this
conclusion and delineate the still unrevealed process of
HPC mobilization by G-CSF following chemotherapy.
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